Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting

Authors

Nicholas Yared, Henry Ford HealthFollow
Smitha Gudipati, Henry Ford HealthFollow
Shannon Payne, Henry Ford HealthFollow
Indira Brar, Henry Ford HealthFollow

Recommended Citation

Yared N, Gudipati S, Payne S, and Brar I. Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting. Open Forum Infect Dis 2025;12(7):349.

Document Type

Article

Publication Date

7-1-2025

Publication Title

Open Forum Infect Dis

Abstract

Fifty-eight people with HIV switched to long-acting cabotegravir and rilpivirine in a real-world clinic setting had higher discontinuation rates because of virologic failure, side effects, or nonadherence compared to clinical trials. Archived proviral genotype testing before long-active cabotegravir and rilpivirine switch should be considered to reduce virologic failure risk.

PubMed ID

40606062

Volume

12

Issue

7

First Page

349

Last Page

349